English

AMICUS THERAPEUTICS, INC.

EDGAR

FOLD Current report (8-K) · filed 2026-03-03

Annual consolidated revenue for 2025: about USD 634.2M, using the latest reported figures. The previous period, 2024, was about USD 528.3M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

185 million USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 634210000 USD Source
Revenue: 448998000 USD Source

Operating margin

8.61%

2025 Q4 · %

Exact inputs and evidence

Operating Income: 32789000 USD Source
Operating Income: 16843000 USD Source
Revenue: 634210000 USD Source
Revenue: 448998000 USD Source

Operating cash flow

16.3 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 33145000 USD Source
Operating Cash Flow: 16892000 USD Source

Free cash flow

16 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: 33145000 USD Source
Operating Cash Flow: 16892000 USD Source
Capital Expenditure: 3296000 USD Source
Capital Expenditure: 2997000 USD Source

Cash and cash equivalents: 214 million USD 2025-12-31 Source
Exact value

214010000 USD
Long-term debt including current maturities: 393 million USD 2025-12-31 Source
Exact value

392660000 USD
Shares outstanding: 311 million shares 2025-12-31 Source
Exact value

310853963 shares

Reported share-count change

3.95% · 11.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

299041653 shares · 2024-12-31· Source
310853963 shares · 2025-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

634 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 125249000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 154688000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 169061000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 634210000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 448998000 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-03-03.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 7 of 11 periods available· newest 2025-12-31
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+20%

Prior period

USD 528.3 million

2024-01-01 – 2024-12-31
Current period

USD 634.21 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

634210000 − 528295000 = 105915000 USD

528295000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
634210000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Year-over-year change in Revenue: 105915000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 634210000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1392524 Filing: 000117887926000005 Input fundies:Revenue: 528295000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1393508 Filing: 000117887926000005
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 29 million

Prior period

−USD 56.11 million

2024-01-01 – 2024-12-31
Current period

−USD 27.11 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-27110000 − -56106000 = 28996000 USD

-56106000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-27110000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Year-over-year change in Net income: 28996000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -27110000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1990725 Filing: 000117887926000005 Input fundies:NetIncome: -56106000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1991499 Filing: 000117887926000005
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 67.04 million

Prior period

−USD 33.89 million

2024-01-01 – 2024-12-31
Current period

USD 33.15 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

33145000 − -33891000 = 67036000 USD

-33891000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
33145000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Year-over-year change in Operating cash flow: 67036000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 33145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1283643 Filing: 000117887926000005 Input fundies:OperatingCashFlow: -33891000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1284526 Filing: 000117887926000005
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-7.2%

Prior period

USD 3.55 million

2024-01-01 – 2024-12-31
Current period

USD 3.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

3296000 − 3553000 = -257000 USD

3553000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
3296000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Year-over-year change in Capital expenditure: -257000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3296000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1290806 Filing: 000117887926000005 Input fundies:CapitalExpenditure: 3553000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1291395 Filing: 000117887926000005
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 634.21 million 100% of revenue
Cost of revenue USD 72.93 million 11% of revenue
Operating expenses USD 528.49 million 83% of revenue
Operating income USD 32.79 million 5.2% of revenue
Tax, interest and other Derived USD 59.9 million 9.4% of revenue
Net income −USD 27.11 million −4.3% of revenue

Cash

Operating cash flow USD 33.15 million 5.2% of revenue
Capital expenditure USD 3.3 million 0.5% of revenue
Free cash flow Derived USD 29.85 million 4.7% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 267% of revenue.
2020 Operating loss: operating costs were 195% of revenue.
2021 Operating loss: operating costs were 168% of revenue.
2022 Operating loss: operating costs were 164% of revenue.
2023 Operating loss: operating costs were 119% of revenue.
2024 Net loss: net income was −11% of revenue.
2025 Net loss: net income was −4.3% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	182237000	486274000 Derived	-304037000	52351000 Derived	-356388000	-270428000 Derived	Source 2019-01-01 – 2019-12-31: 182237000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -304037000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -356388000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -250416000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 20012000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	260886000	507884000 Derived	-246998000	29854000 Derived	-276852000	-236517000 Derived	Source 2020-01-01 – 2020-12-31: 260886000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -246998000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -276852000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -233290000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3227000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	305514000	511948000 Derived	-206434000	44026000 Derived	-250460000	-206375000 Derived	Source 2021-01-01 – 2021-12-31: 305514000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -206434000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -250460000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -202491000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3884000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	329233000	541353000 Derived	-212120000	24448000 Derived	-236568000	-170341000 Derived	Source 2022-01-01 – 2022-12-31: 329233000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -212120000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -236568000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -166575000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3766000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	399356000	476567000 Derived	-77211000	74373000 Derived	-151584000	-76531000 Derived	Source 2023-01-01 – 2023-12-31: 399356000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -77211000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -151584000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -69091000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 7440000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	528295000	503419000 Derived	24876000	80982000 Derived	-56106000	-37444000 Derived	Source 2024-01-01 – 2024-12-31: 528295000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: 24876000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -56106000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -33891000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3553000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	634210000	601421000 Derived	32789000	59899000 Derived	-27110000	29849000 Derived	Source 2025-01-01 – 2025-12-31: 634210000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: 32789000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -27110000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 33145000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 3296000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 634.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	182237000	Revenue: 182237000 Open source
20202020-12-31	Revenue	260886000	Revenue: 260886000 Open source
20212021-12-31	Revenue	305514000	Revenue: 305514000 Open source
20222022-12-31	Revenue	329233000	Revenue: 329233000 Open source
20232023-12-31	Revenue	399356000	Revenue: 399356000 Open source
20242024-12-31	Revenue	528295000	Revenue: 528295000 Open source
20252025-12-31	Revenue	634210000	Revenue: 634210000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

20% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 182237000 Open source
20202020-12-31	Year over year	43.2%	Revenue: 260886000 Open source Revenue: 182237000 Open source
20212021-12-31	Year over year	17.1%	Revenue: 305514000 Open source Revenue: 260886000 Open source
20222022-12-31	Year over year	7.8%	Revenue: 329233000 Open source Revenue: 305514000 Open source
20232023-12-31	Year over year	21.3%	Revenue: 399356000 Open source Revenue: 329233000 Open source
20242024-12-31	Year over year	32.3%	Revenue: 528295000 Open source Revenue: 399356000 Open source
20252025-12-31	Year over year	20%	Revenue: 634210000 Open source Revenue: 528295000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 5.2% 2025

Net margin -4.3% 2025

Free cash flow margin 4.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-166.8%	Operating Income: -304037000 Open source Revenue: 182237000 Open source
20202020-12-31	Operating margin	-94.7%	Operating Income: -246998000 Open source Revenue: 260886000 Open source
20212021-12-31	Operating margin	-67.6%	Operating Income: -206434000 Open source Revenue: 305514000 Open source
20222022-12-31	Operating margin	-64.4%	Operating Income: -212120000 Open source Revenue: 329233000 Open source
20232023-12-31	Operating margin	-19.3%	Operating Income: -77211000 Open source Revenue: 399356000 Open source
20242024-12-31	Operating margin	4.7%	Operating Income: 24876000 Open source Revenue: 528295000 Open source
20252025-12-31	Operating margin	5.2%	Operating Income: 32789000 Open source Revenue: 634210000 Open source
20192019-12-31	Net margin	-195.6%	Net Income: -356388000 Open source Revenue: 182237000 Open source
20202020-12-31	Net margin	-106.1%	Net Income: -276852000 Open source Revenue: 260886000 Open source
20212021-12-31	Net margin	-82%	Net Income: -250460000 Open source Revenue: 305514000 Open source
20222022-12-31	Net margin	-71.9%	Net Income: -236568000 Open source Revenue: 329233000 Open source
20232023-12-31	Net margin	-38%	Net Income: -151584000 Open source Revenue: 399356000 Open source
20242024-12-31	Net margin	-10.6%	Net Income: -56106000 Open source Revenue: 528295000 Open source
20252025-12-31	Net margin	-4.3%	Net Income: -27110000 Open source Revenue: 634210000 Open source
20192019-12-31	Free cash flow margin	-148.4%	Revenue: 182237000 Open source Operating Cash Flow: -250416000 Open source Capital Expenditure: 20012000 Open source
20202020-12-31	Free cash flow margin	-90.7%	Revenue: 260886000 Open source Operating Cash Flow: -233290000 Open source Capital Expenditure: 3227000 Open source
20212021-12-31	Free cash flow margin	-67.6%	Revenue: 305514000 Open source Operating Cash Flow: -202491000 Open source Capital Expenditure: 3884000 Open source
20222022-12-31	Free cash flow margin	-51.7%	Revenue: 329233000 Open source Operating Cash Flow: -166575000 Open source Capital Expenditure: 3766000 Open source
20232023-12-31	Free cash flow margin	-19.2%	Revenue: 399356000 Open source Operating Cash Flow: -69091000 Open source Capital Expenditure: 7440000 Open source
20242024-12-31	Free cash flow margin	-7.1%	Revenue: 528295000 Open source Operating Cash Flow: -33891000 Open source Capital Expenditure: 3553000 Open source
20252025-12-31	Free cash flow margin	4.7%	Revenue: 634210000 Open source Operating Cash Flow: 33145000 Open source Capital Expenditure: 3296000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 33.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-250416000	Operating Cash Flow: -250416000 Open source
20202020-12-31	Operating cash flow	-233290000	Operating Cash Flow: -233290000 Open source
20212021-12-31	Operating cash flow	-202491000	Operating Cash Flow: -202491000 Open source
20222022-12-31	Operating cash flow	-166575000	Operating Cash Flow: -166575000 Open source
20232023-12-31	Operating cash flow	-69091000	Operating Cash Flow: -69091000 Open source
20242024-12-31	Operating cash flow	-33891000	Operating Cash Flow: -33891000 Open source
20252025-12-31	Operating cash flow	33145000	Operating Cash Flow: 33145000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 29.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-270428000	Operating Cash Flow: -250416000 Open source Capital Expenditure: 20012000 Open source
20202020-12-31	Free cash flow	-236517000	Operating Cash Flow: -233290000 Open source Capital Expenditure: 3227000 Open source
20212021-12-31	Free cash flow	-206375000	Operating Cash Flow: -202491000 Open source Capital Expenditure: 3884000 Open source
20222022-12-31	Free cash flow	-170341000	Operating Cash Flow: -166575000 Open source Capital Expenditure: 3766000 Open source
20232023-12-31	Free cash flow	-76531000	Operating Cash Flow: -69091000 Open source Capital Expenditure: 7440000 Open source
20242024-12-31	Free cash flow	-37444000	Operating Cash Flow: -33891000 Open source Capital Expenditure: 3553000 Open source
20252025-12-31	Free cash flow	29849000	Operating Cash Flow: 33145000 Open source Capital Expenditure: 3296000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

71.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	44%	Total Liabilities: 373782000 Open source Total Assets: 850207000 Open source
20202020-12-31	Liabilities / assets	67.7%	Total Liabilities: 600140000 Open source Total Assets: 886520000 Open source
20212021-12-31	Liabilities / assets	66%	Total Liabilities: 597771000 Open source Total Assets: 905140000 Open source
20222022-12-31	Liabilities / assets	83%	Total Liabilities: 601120000 Open source Total Assets: 724167000 Open source
20232023-12-31	Liabilities / assets	79.4%	Total Liabilities: 617706000 Open source Total Assets: 777880000 Open source
20242024-12-31	Liabilities / assets	75.3%	Total Liabilities: 590988000 Open source Total Assets: 785033000 Open source
20252025-12-31	Liabilities / assets	71.1%	Total Liabilities: 675629000 Open source Total Assets: 949870000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.84× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	4.04×	Current Assets: 520073000 Open source Current Liabilities: 128812000 Open source
20202020-12-31	Current assets / current liabilities	4.47×	Current Assets: 579469000 Open source Current Liabilities: 129676000 Open source
20212021-12-31	Current assets / current liabilities	4.09×	Current Assets: 596834000 Open source Current Liabilities: 145975000 Open source
20222022-12-31	Current assets / current liabilities	3.05×	Current Assets: 423816000 Open source Current Liabilities: 139018000 Open source
20232023-12-31	Current assets / current liabilities	2.88×	Current Assets: 483061000 Open source Current Liabilities: 167689000 Open source
20242024-12-31	Current assets / current liabilities	3.39×	Current Assets: 504736000 Open source Current Liabilities: 148702000 Open source
20252025-12-31	Current assets / current liabilities	2.84×	Current Assets: 676173000 Open source Current Liabilities: 237828000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 200.04 million Exact value Exact value: -200042000 USD 2016-01-01 – 2016-12-31: -200042000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2016-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -200042000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -200042000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/fold-20181231.xml#301192 Filing: 000117887919000024 The citation records this snapshot. The page link may show a newer release later.	−USD 150.15 million Exact value Exact value: -150147000 USD 2016-01-01 – 2016-12-31: -150147000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2016-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -150147000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -150147000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/fold-20181231.xml#300243 Filing: 000117887919000024 The citation records this snapshot. The page link may show a newer release later.	USD 5.95 million Exact value Exact value: 5951000 USD 2016-01-01 – 2016-12-31: 5951000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2016-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 5951000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5951000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/fold-20181231.xml#317237 Filing: 000117887919000024 The citation records this snapshot. The page link may show a newer release later.	−USD 156.1 million Calculation and evidence -150147000 − 5951000 USD Exact free cash flow: -156098000 USD 2016-01-01 – 2016-12-31: -150147000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5951000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2016-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -156098000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -150147000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/fold-20181231.xml#300243 Filing: 000117887919000024 Input fundies:CapitalExpenditure: 5951000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887919000024/fold-20181231.xml#317237 Filing: 000117887919000024 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 284 million Exact value Exact value: -284002000 USD 2017-01-01 – 2017-12-31: -284002000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2017-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -284002000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -284002000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm#2575936 Filing: 000117887920000015 The citation records this snapshot. The page link may show a newer release later.	−USD 213.7 million Exact value Exact value: -213695000 USD 2017-01-01 – 2017-12-31: -213695000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2017-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -213695000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -213695000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm#1586337 Filing: 000117887920000015 The citation records this snapshot. The page link may show a newer release later.	USD 4.53 million Exact value Exact value: 4526000 USD 2017-01-01 – 2017-12-31: 4526000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2017-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 4526000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4526000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm#1596463 Filing: 000117887920000015 The citation records this snapshot. The page link may show a newer release later.	−USD 218.22 million Calculation and evidence -213695000 − 4526000 USD Exact free cash flow: -218221000 USD 2017-01-01 – 2017-12-31: -213695000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4526000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2017-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -218221000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -213695000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm#1586337 Filing: 000117887920000015 Input fundies:CapitalExpenditure: 4526000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/amicus1231201910-k.htm#1596463 Filing: 000117887920000015 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 349 million Exact value Exact value: -348995000 USD 2018-01-01 – 2018-12-31: -348995000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2018-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -348995000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -348995000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm#2573407 Filing: 000117887921000004 The citation records this snapshot. The page link may show a newer release later.	−USD 299.96 million Exact value Exact value: -299955000 USD 2018-01-01 – 2018-12-31: -299955000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2018-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -299955000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -299955000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm#1560849 Filing: 000117887921000004 The citation records this snapshot. The page link may show a newer release later.	USD 6.31 million Exact value Exact value: 6308000 USD 2018-01-01 – 2018-12-31: 6308000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2018-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 6308000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6308000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm#1570972 Filing: 000117887921000004 The citation records this snapshot. The page link may show a newer release later.	−USD 306.26 million Calculation and evidence -299955000 − 6308000 USD Exact free cash flow: -306263000 USD 2018-01-01 – 2018-12-31: -299955000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6308000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2018-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -306263000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -299955000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm#1560849 Filing: 000117887921000004 Input fundies:CapitalExpenditure: 6308000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887921000004/fold-20201231.htm#1570972 Filing: 000117887921000004 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 356.39 million Exact value Exact value: -356388000 USD 2019-01-01 – 2019-12-31: -356388000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2019-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -356388000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -356388000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-20211231.htm#2376019 Filing: 000117887922000006 The citation records this snapshot. The page link may show a newer release later.	−USD 250.42 million Exact value Exact value: -250416000 USD 2019-01-01 – 2019-12-31: -250416000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2019-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -250416000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -250416000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-20211231.htm#1430397 Filing: 000117887922000006 The citation records this snapshot. The page link may show a newer release later.	USD 20.01 million Exact value Exact value: 20012000 USD 2019-01-01 – 2019-12-31: 20012000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2019-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 20012000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20012000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-20211231.htm#1440582 Filing: 000117887922000006 The citation records this snapshot. The page link may show a newer release later.	−USD 270.43 million Calculation and evidence -250416000 − 20012000 USD Exact free cash flow: -270428000 USD 2019-01-01 – 2019-12-31: -250416000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 20012000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2019-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -270428000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -250416000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-20211231.htm#1430397 Filing: 000117887922000006 Input fundies:CapitalExpenditure: 20012000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-20211231.htm#1440582 Filing: 000117887922000006 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 276.85 million Exact value Exact value: -276852000 USD 2020-01-01 – 2020-12-31: -276852000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2020-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -276852000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -276852000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887923000004/fold-20221231.htm#2258683 Filing: 000117887923000004 The citation records this snapshot. The page link may show a newer release later.	−USD 233.29 million Exact value Exact value: -233290000 USD 2020-01-01 – 2020-12-31: -233290000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2020-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -233290000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -233290000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887923000004/fold-20221231.htm#1396390 Filing: 000117887923000004 The citation records this snapshot. The page link may show a newer release later.	USD 3.23 million Exact value Exact value: 3227000 USD 2020-01-01 – 2020-12-31: 3227000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2020-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 3227000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3227000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887923000004/fold-20221231.htm#1406575 Filing: 000117887923000004 The citation records this snapshot. The page link may show a newer release later.	−USD 236.52 million Calculation and evidence -233290000 − 3227000 USD Exact free cash flow: -236517000 USD 2020-01-01 – 2020-12-31: -233290000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3227000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2020-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -236517000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -233290000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887923000004/fold-20221231.htm#1396390 Filing: 000117887923000004 Input fundies:CapitalExpenditure: 3227000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887923000004/fold-20221231.htm#1406575 Filing: 000117887923000004 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 250.46 million Exact value Exact value: -250460000 USD 2021-01-01 – 2021-12-31: -250460000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2021-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -250460000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -250460000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887924000003/fold-20231231.htm#1924073 Filing: 000117887924000003 The citation records this snapshot. The page link may show a newer release later.	−USD 202.49 million Exact value Exact value: -202491000 USD 2021-01-01 – 2021-12-31: -202491000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2021-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -202491000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -202491000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887924000003/fold-20231231.htm#1292655 Filing: 000117887924000003 The citation records this snapshot. The page link may show a newer release later.	USD 3.88 million Exact value Exact value: 3884000 USD 2021-01-01 – 2021-12-31: 3884000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2021-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 3884000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3884000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887924000003/fold-20231231.htm#1299294 Filing: 000117887924000003 The citation records this snapshot. The page link may show a newer release later.	−USD 206.38 million Calculation and evidence -202491000 − 3884000 USD Exact free cash flow: -206375000 USD 2021-01-01 – 2021-12-31: -202491000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3884000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2021-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -206375000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -202491000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887924000003/fold-20231231.htm#1292655 Filing: 000117887924000003 Input fundies:CapitalExpenditure: 3884000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887924000003/fold-20231231.htm#1299294 Filing: 000117887924000003 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 236.57 million Exact value Exact value: -236568000 USD 2022-01-01 – 2022-12-31: -236568000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2022-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -236568000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -236568000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm#1929030 Filing: 000117887925000003 The citation records this snapshot. The page link may show a newer release later.	−USD 166.58 million Exact value Exact value: -166575000 USD 2022-01-01 – 2022-12-31: -166575000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2022-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -166575000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -166575000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm#1288902 Filing: 000117887925000003 The citation records this snapshot. The page link may show a newer release later.	USD 3.77 million Exact value Exact value: 3766000 USD 2022-01-01 – 2022-12-31: 3766000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2022-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 3766000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3766000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm#1295541 Filing: 000117887925000003 The citation records this snapshot. The page link may show a newer release later.	−USD 170.34 million Calculation and evidence -166575000 − 3766000 USD Exact free cash flow: -170341000 USD 2022-01-01 – 2022-12-31: -166575000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3766000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2022-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -170341000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -166575000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm#1288902 Filing: 000117887925000003 Input fundies:CapitalExpenditure: 3766000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887925000003/fold-20241231.htm#1295541 Filing: 000117887925000003 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 151.58 million Exact value Exact value: -151584000 USD 2023-01-01 – 2023-12-31: -151584000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2023-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -151584000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -151584000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1992273 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	−USD 69.09 million Exact value Exact value: -69091000 USD 2023-01-01 – 2023-12-31: -69091000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2023-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -69091000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69091000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1285413 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	USD 7.44 million Exact value Exact value: 7440000 USD 2023-01-01 – 2023-12-31: 7440000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2023-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 7440000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7440000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1291984 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	−USD 76.53 million Calculation and evidence -69091000 − 7440000 USD Exact free cash flow: -76531000 USD 2023-01-01 – 2023-12-31: -69091000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 7440000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2023-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -76531000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69091000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1285413 Filing: 000117887926000005 Input fundies:CapitalExpenditure: 7440000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1291984 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 56.11 million Exact value Exact value: -56106000 USD 2024-01-01 – 2024-12-31: -56106000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2024-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -56106000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56106000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1991499 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	−USD 33.89 million Exact value Exact value: -33891000 USD 2024-01-01 – 2024-12-31: -33891000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2024-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: -33891000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33891000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1284526 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	USD 3.55 million Exact value Exact value: 3553000 USD 2024-01-01 – 2024-12-31: 3553000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2024-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 3553000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3553000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1291395 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	−USD 37.44 million Calculation and evidence -33891000 − 3553000 USD Exact free cash flow: -37444000 USD 2024-01-01 – 2024-12-31: -33891000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3553000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2024-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: -37444000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33891000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1284526 Filing: 000117887926000005 Input fundies:CapitalExpenditure: 3553000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1291395 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 27.11 million Exact value Exact value: -27110000 USD 2025-01-01 – 2025-12-31: -27110000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Net Income: -27110000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27110000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1990725 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	USD 33.15 million Exact value Exact value: 33145000 USD 2025-01-01 – 2025-12-31: 33145000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Operating Cash Flow: 33145000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 33145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1283643 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	USD 3.3 million Exact value Exact value: 3296000 USD 2025-01-01 – 2025-12-31: 3296000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Capital Expenditure: 3296000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3296000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1290806 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.	USD 29.85 million Calculation and evidence 33145000 − 3296000 USD Exact free cash flow: 29849000 USD 2025-01-01 – 2025-12-31: 33145000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 3296000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AMICUS THERAPEUTICS, INC. · 2025-12-31 AMICUS THERAPEUTICS, INC. (edgar:1178879) Free cash flow: 29849000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1178879?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 33145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1283643 Filing: 000117887926000005 Input fundies:CapitalExpenditure: 3296000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1178879/000117887926000005/fold-20251231.htm#1290806 Filing: 000117887926000005 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

272 filings · 4,892 latest values · 4,892 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001178879, 1178879, FOLD, edgar:1178879

Also known as AMICUS THERAPEUTICS INC, AMICUS THERAPEUTICS, INC., Amicus Therapeutics, Inc.

AMICUS THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation